2Eickelberg O, Pansky A, Koehler E, et al. Molecular mechanisms of TGF(betta) antagonism by interferon-γ and cycloporine A in lung fibrosis ,2001,15 (3) :797 - 806.
5Ziesche R, Hofbauer E, Wittmann K, et al. A preliminary study of long-term treatment with interferon-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med, 1999,341: 1264 - 1269.
6Raghu G, Brown KK, Bradford WZ, et al. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med,2004,350:125 - 133.
7Sanjay kalra MD ,james P, utz MD, et al. Interferon Gamma-1b Therapy for Advanced Idiopathic Pulmonary Fibrosis. Mayo Clin Proc, 2003, 78 : 1082 - 1087.
8Hillman R, Tchamouroff S, Denning DW, et al. A phase Ⅲ study of diseases or familial IPF, may have an increased risk of adverse recombinant human interferon gamma to prevent opportunistic in-outcome when treated with interferon-1b, fections in advanced HIV disease. AIDS Res Hum Retroviruses ,2001,17 :789 - 797.
9Honor I,Nunes H, Groussard O, et al. Acute Respiratory. Failure after Interferon-γTherapy of End-Stage Pulmonary Fibrosis. Am J Respir Crit Care Med,2003 ,167 :953 -957.
10Selman M. A dark side of interferon-γ in the treatment of idiopathic pulmonary fibrosis? Am J Respir Crit Care Med,2003 ,167 :945 -946.
二级参考文献20
1Wallace WA, Ramage EA, Lamb D, et al. A type-2 (Th2-1ike) pattern of immune response predominates in the pulmonary interstitium of patients with cryptogenic fibrosing alveolitis. Clin Exp Immunol, 1995,101(3): 436-441
2Gurujeyalakshmi G, Giri SN. Molecular mechanisms of antifibrotic effect of interferon gamma in bleomycin-mouse model of lung fibrosis: downregtulation of TGF - beta and procollagen Ⅰ and Ⅲ gene expression. Exp Lung Res, 1995, 21(5) :791 - 808
3Lasky JA, Ortiz LA. Antifibrotic therapy for the treatment of pulmonary fibrosis. Am J Med Sci, 2001, 322(4) :213 - 221
4Ando M, Miyazaki E, Fukami T, et al. Interleukin-4-producing cells in idiopathic pulmonary fibrosis: an immunohistochemical study. Respirology, 1999, 4(4):383-391
5Hagimoto N, Kuwano K, Miyazaki H, et al. Induction of apoptosis and pulmonary fibrosis in mice in response to ligation of Fas antigen. Am J Respir Cell Mol Bio, 1997, 17(3): 272-278
6Maeyama T,Kuwano K,Kawasaki M,et al.Attenuation of bleomycin-Induced pneumopathy in mice by monoclonal antibody to interleukin-13[J].Am J Physiol,,2001,280(6):1128-1137.
7Hashimoto S,Gon Y,Takeshita I,et al.IL-4 and IL-13 induce myofibroblastic phenotype of human lung fibroblasts through c-Jun NH2-terminal kinase-dependent pathway[J].J Allergy Clin Immunol,2001,107(6):1001-1008.
8Doucet C, Brouty-Boye D, Pottin-Clemenceau C, et al. Interleukin(IL) 4 and IL-13 act on human lung fibroblasts. Implication in asthma[J]. J Clin Invest ,1998,101(10):2129-2139.
9Spinozzi F, Agea E, Russano A, et al.Th2-type cytokines and the Fas way to pulmonary fibrosis:comment on the article by Atamas et al[J]. Arthritis Rheum,2000,43(1):236-238.
10Lukacs NW, Hogaboam C, Chensue SW, et al. Typel/type2 cytokine paradigm and the progression of pulmonary fibrosis. Chest, 2001,120( 1Suppl): 5S-8S.
